Abstract:

Objective To evaluate the antihypertensive efficacy and safety of rosuvastatin combined with antihypertensive drugs on hypertension patients combined with dyslipidemia. Methods Randomized controlled trials (RCT) reporting the treatment of rosuvastatin combined with antihypertensive drugs versus the monotherapy of antihypertensive drugs in hypertension patients combined with dyslipidemia published before November 2015 were systematically searched in the online databases of PubMed, The Cochrane Library and the Web of Science Core Collection (including the SCIE, SSCI, A&HCI, and CPCI databases). Two investigators were independently responsible for screening eligible literatures based on the inclusion and exclusion criteria, extracting data, cross-checking and evaluating the quality. Meta-analysis was performed using STATA12.0 software. Results A total of 11 RCTs involving 1275 hypertension patients combined with dyslipidemia were included. Among them, 696 patients were included in the experimental group (rosuvastatin combined with antihypertensive drugs) and 579 were in the control group (monotherapy of antihypertensive drugs). Meta-analysis showed that the blood pressure decrease in the experimental group was significantly greater than that of the control group (systolic blood pressure: W M D=-1.97, 95% C I: -3.55, -0.38, P=0.02; diastolic blood pressure: W M D=-1.24, 95% C I: -2.20, -0.29, P=0.01). Subgroup analysis showed the tripe therapy of rosuvastatin combined with two types of antihypertensive drugs (amlodipine + sartan) presented the most significant antihypertensive effect (systolic blood pressure: W M D=-4.06, 95% C I: -6.84, -1.29, P=0.004; diastolic blood pressure: W M D=-1.46, 95% C I: -2.90, -0.02, P=0.047). No significant difference in the incidence of adverse events was found between the experimental group and control group ( O R=1.17, 95% C I: 0.73-1.86, P=0.52). Conclusion Rosuvastatin combined with antihypertensive drugs lowers blood pressure more effectively compared with the monotherapy of antihypertensive drugs, and the triple therapy of rosuvastatin, amlodipine and sartan has a more significant antihypertensive effect without increasing adverse drug effects.

Key words: rosuvastatin, amlodipine, sartan antihypertensive drugs, meta-analysis, randomized controlled study